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http://dx.doi.org/10.1016/j.ccr.2013.01.007SUMMARYSignificant endeavor has been applied to identify functional therapeutic targets in glioblastoma (GBM) to halt
the growth of this aggressive cancer. We show that the receptor tyrosine kinase EphA3 is frequently overex-
pressed in GBM and, in particular, in the most aggressive mesenchymal subtype. Importantly, EphA3 is
highly expressed on the tumor-initiating cell population in glioma and appears critically involved in maintain-
ing tumor cells in a less differentiated state bymodulatingmitogen-activated protein kinase signaling. EphA3
knockdown or depletion of EphA3-positive tumor cells reduced tumorigenic potential to a degree compa-
rable to treatment with a therapeutic radiolabelled EphA3-specific monoclonal antibody. These results iden-
tify EphA3 as a functional, targetable receptor in GBM.INTRODUCTION
Glioblastoma (GBM) is the most common primary brain cancer.
Standard treatment involves surgical resection, followed by radi-
ation and temozolomide chemotherapy (Behin et al., 2003).
Therapy is rarely curative due to the infiltrative nature of these
tumors and their resistance to radiation and chemotherapy.
Median survival is <15 months and median progression-free
survival is <7 months (Stupp et al., 2005). This dismal situation
motivates a search for new therapies, in particular those that
target tumor-propagating cells. Gene expression profiling,
together with DNA mutation data, has identified four GBM
subtypes (proneural, neural, classical, and mesenchymal) (CarroSignificance
Although debate still surrounds the cancer stem cell hypothe
cells in a less differentiated, tumorigenic state exist within the
be responsible for tumor recurrence following treatment. Her
has a functional role in maintaining less differentiated, tumor
kinase signaling. EphA3 is lowly expressed in adult tissues and
target in GBM.
238 Cancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc.et al., 2010; Verhaak et al., 2010). There is also accumulating
evidence that at least some GBMs arise from developmentally
arrested neural progenitor or stem cells (Pardal et al., 2003;
Reya et al., 2001; Singh et al., 2004), although this may not be
universally true (Visvader, 2011). Despite this controversy, cells
with dedifferentiated properties are thought to be responsible
for tumor recurrence following treatment (Dick, 2008), and their
intrinsic resistance to both chemotherapy and radiation requires
new strategies to eradicate them (Bao et al., 2006).
Eph receptors are the largest family of receptor tyrosine
kinases and have vital functions, including cell adhesion, migra-
tion, and axon guidance, during development and homeostasis
(Flanagan and Vanderhaeghen, 1998; Holder and Klein, 1999;sis in solid tumors, such as GBM, there is agreement that
se highly heterogeneous tumors. These cells are thought to
e, we demonstrate that in EphA3-expressing GBM, EphA3
-initiating cells by modulation of mitogen-activated protein
therefore represents a relatively tumor-specific therapeutic
Figure 1. EphA3 Is Expressed Highly in Glioma and Is Overrepre-
sented on Mesenchymal Tumors
(A) EPHA3 overexpression was tested by qPCR in glioma clinical specimens
(n = 80) compared to normal brain tissue (n = 12; p = 0.001; unpaired t test with
Welsh’s correction). EPHA3mRNA levels were negligible in normal brain while
40% of clinical specimens (32/80) expressed detectable levels of EPHA3
mRNA (more than two copies per 1,000 b-actin; further defined in Figure S1).
Table S1 lists the specimens tested.
(B) Flow cytometric analysis of EphA3 protein expression in dissociated GBM
clinical specimens.
(C) Linear regression analysis of EPHA3 mRNA (qPCR) and EphA3 protein
(mean channel fluorescence) levels in serum-free cultures (n = 11) shows
a positive correlation (r2 = 0.675, p = 0.0019). See also Figure S1.
(D) EPHA3 microarray expression data were compared to GBM subtype
classification (mesenchymal, classical, proneural, neural) in GBM specimens
from the TCGA database (n = 173). Samples expressing EPHA3 >1.4-fold (n =
47) showed an overrepresentation of mesenchymal tumors (60%) and an
underrepresentation of neural tumors (9%). The difference between each
group was significant (p = 0.001) as assessed by multivariate analysis. See
also Figures S1A–S1F.
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EphA3 Is Functional and Targetable in GBMMann et al., 2002; Wilkinson, 2000). Eph receptors and ephrin
ligands tend to be most highly expressed during development,
and evidence suggests a role in regulation of stem cell differen-
tiation and cell fate determination (Aoki et al., 2004; Conover
et al., 2000; Holmberg et al., 2006; Lickliter et al., 1996; Wang
et al., 2004). Ephrins and Eph receptors have been found to be
aberrantly expressed in many cancers, including GBM (Pas-
quale, 2010). Family members implicated in gene deregulation
and function in GBM include EphA2, EphA7, EphB2, and eph-
rin-A5 (Li et al., 2009; Nakada et al., 2004; Wang et al., 2008;
Wykosky et al., 2005).
EphA3 is expressed in embryonic tissues including the brain,
spinal cord, axial muscles, lungs, kidneys, and heart (KilpatrickCet al., 1996) and appears to play a critical role in epithelial-to-
mesenchymal transition (EMT) (Stephen et al., 2007). EphA3
mutations have been identified that suggest a tumor-suppressor
role in some cancers (Davies et al., 2005). Conversely, overex-
pression of EphA3 has been observed in some cancers,
including leukemia, lymphoma, lung cancers, melanomas, and
gastric carcinoma (Boyd et al., 1992; Chiari et al., 2000; Dottori
et al., 1999; Lawrenson et al., 2002; Wicks et al., 1992; Xi
et al., 2012). EphA3 somatic mutations, which map to highly
conserved regions of the gene, have been identified in GBM
(Balakrishnan et al., 2007; Lisabeth et al., 2012).
Given the expression of EphA3 in many human cancers and its
role in EMT, we explored the expression and function of EphA3 in
GBM and, in particular, the mesenchymal subtype, which has a
more aggressive and less differentiated phenotype with a poorer
prognosis (Phillips et al., 2006).
RESULTS
EphA3 Is Highly Expressed in Glioma and Is
Overrepresented on Mesenchymal GBM
To investigate EphA3 expression in brain cancer, we assessed
messenger RNA (mRNA) and protein levels in a series of clinical
glioma specimens and specimen-derived early passage cell
lines. A bank of 80 human glioma clinical specimens was
collected of which 74% were GBM (WHO grade IV) (Table S1
available online). Quantitative PCR (qPCR) was performed on
these tumors and 12 normal human brain specimens (Figure 1A).
EPHA3 mRNA levels were low in normal brain whereas 40% of
clinical specimens (32/80) expressed significantly (p < 0.01)
higher levels of EPHA3 mRNA. EphA3 protein expression was
assessed using flow cytometry of dissociated GBM tumor
samples; representative expression profiles are shown in Fig-
ure 1B. In some cases essentially all cells were positive, whereas
in others only a subset showed significant expression.
To further explore EphA3 expression, we analyzed a panel of
early passage (less than five passages) cell lines from primary
GBM specimens. Lines were grown in serum-free medium on
a laminin substratum, because these conditions are reported to
maintain the phenotype and genotype of the original tumor and
enrich for tumor-initiating cells (Pollard et al., 2009). qPCR and
flow cytometry were used to analyze EphA3 expression in these
cultures (Figures S1A and S1B). Results showed that a greater
proportion of cultures expressedEPHA3 (60%, n = 15) compared
to clinical specimens (40%, n = 80). Flow cytometry also revealed
a greater than expected level of EphA3 expression when
compared to the original tissue specimens (data not shown).
To determine the correlation between mRNA and protein
expression, we analyzed primary serum-free cultures (n = 11)
to compare mRNA (qPCR) and protein (mean channel fluores-
cence) levels (Figure 1C). Linear regression analysis showed
a strong correlation (r2 = 0.675 p = 0.0019) between mRNA
and protein expression. EphA3 protein was detectable by flow
cytometry when GBM lines expressed mRNA levels of two or
more copies per 1,000 b-actin (Figure S1C). Additional analysis
of ephrin expression by qPCR was performed in six primary
serum-free cultures (Figure S1D). All samples had relatively low
expression and, in particular, of the high-affinity EPHA3 ligand
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Figure 2. EphA3 Neutralization Prevents
Tumorsphere Formation and Induces
Neuronal and Glial Cell Differentiation
(A) Immunofluorescence staining of EphA3 in three
early passage primary GBM cultures (BAH1, WK1,
and SJH1) reveals EphA3 is abundantly expressed
and localized at the cell membrane.
(B) EphA3 protein level was downregulated using
two EPHA3 shRNA sequences.
(C) EphA3 downregulation in primary GBM
cultures was quantified using flow cytometric
analysis. The most effective KD in BAH1 and WK1
cells was achieved using shRNA sequence 1,
whereas shRNA sequence 2 was proven more
effective in SJH1 cells. Staining levels were
compared to control shRNA.
(D and E) Downregulation of EphA3 induced a
partial loss of tumorsphere formation and reduced
proliferation in all three primary GBM lines
following cell passage (*p < 0.05, +SD, n = 3).
(F) EphA3 downregulation coincided with positive
staining of neuronal (bIII-tubulin) and glial (GFAP)
differentiation markers, which was low in control
tumorspheres (data shown for WK1 and SJH1).
(G) EphA3 levels were assessed by flow cytometry
following differentiation of BAH1, WK1, and SJH1
cells. Differentiation was induced by removal of
growth factors and addition of 2% serum. A
reduction in EphA3 was observed in each line
when compared to cells cultured under dediffer-
entiating serum-free conditions.
(H) Immunohistochemical staining of sequential
sections of a GBM clinical specimen and a BAH1
GBM xenografted tumor shows highly discrete
staining between EphA3 and the glial marker
GFAP.
Scale bar represents 20 mM. See also Figures
S2A–S2F.
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EphA3 Is Functional and Targetable in GBMTo investigate if EPHA3 expression correlated with glioma
subtypes, we analyzed a data set of GBM specimens from The
Cancer Genome Atlas Project (TCGA) (n = 173), which had
been assigned GBM subtypes defined by a previous study
(Verhaak et al., 2010). Samples expressing elevated EPHA3
(>1.4-fold; n = 47) showed an overrepresentation of mesen-
chymal tumors (60%) and an underrepresentation of neural
tumors (9%), which was significant by multivariate analysis
(p = 0.0001) (Figure 1D). Furthermore, analysis of EPHA3 alter-
ations, the majority being RNA upregulation, using the TCGA
database revealed that altered EPHA3 led to decreased survival
in patients with mesenchymal subtype GBM (n = 56, p = 0.017;
Figure S1E). Alternatively, using the Rembrandt database,
EPHA3 expression in all gliomas (n = 454) showed a significant
correlation with survival (Figure S1F). Analysis revealed a 2-fold
decrease in EPHA3 expression (n = 160) correlated with
increased survival (p = 0.002), whereas a 2-fold increase in
EPHA3 expression (n = 34) correlated with decreased survival
(p = 0.02).
Loss of EphA3 Prevents Tumorsphere Formation and
Induces Neuronal and Glial Cell Differentiation
Growth under neurosphere culture conditions selects against
survival of terminally differentiated cells, whereas less differenti-240 Cancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc.ated cells respond to growth factors to form ‘‘neurospheres’’
(Reynolds and Weiss, 1992). Under these conditions, a subset
of GBM cells grow as ‘‘tumorspheres’’ and exhibit self-renewal
and retain the capacity to differentiate (Galli et al., 2004). Conse-
quently, to further explore EphA3 function in GBM, we generated
three primary GBMcultures (BAH1,WK1, and SJH1), whichwere
all shown to form orthotopic tumors in immune-compromised
animals; we also used the established GBM cell line U251 grown
as tumorspheres. The subtype of these primary lines was deter-
mined using the microarray method outlined by Verhaak et al.
(2010). BAH1 and SJH1 were derived from GBMs of the neural
subtype while WK1 was established from a mesenchymal
GBM. Immunofluorescence staining for EphA3 showed strong
membranous expression in all of the lines (Figure 2A).
We first investigated the effect of EphA3 knockdown (KD) on
tumorsphere growth using two different EPHA3 small hairpin
RNA (shRNA) sequences, both of which resulted in >90% KD
of EphA3 expression (Figures 2B, 2C, S2A, and S2B). In all four
cell lines, following several passages the sphere-forming capa-
bility of the KD cells was reduced and was accompanied by
increased cell spreading, adherence, and morphological
changes (Figures 2D and S2C). Adherent cells in all three
EphA3 KD primary lines grew slowly under tumorsphere culture
conditions and died following subsequent cell passage. This
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EphA3 Is Functional and Targetable in GBMphenomenon was not observed in U251 cells, which grew slowly
but remained viable (Figure S2D). In contrast, when EphA3 KD
primary cells were grown under serum-free conditions on lami-
nin, all three primary cultures were viable but proliferated slowly
(Figure 2E). To determine whether the morphological changes
following KD were the result of differentiation, cultures were
stained with lineage-specific markers (Figures 2F and S2E).
Positive staining for astrocytic (glial fibrillary acidic protein
[GFAP]) and neuronal (bIII-tubulin) markers, but minimal staining
with the oligodendrocytic (myelin basic protein) lineage marker,
was observed. Control tumorspheres showed minimal staining
for differentiation markers (Figure S2F). We also established
a tetracycline-inducible EphA3 KD system in U251 cells (Figures
S2B–S2E). Whereas EphA3-positive U251 cells formed tumor-
spheres in the absence of tetracycline, tumorsphere formation
and proliferation was greatly reduced following tetracycline-
induced EphA3 KD and was accompanied by expression of
differentiation markers. Following removal of tetracycline,
EphA3 was re-expressed and tumorsphere formation was
restored. As a specificity control for EphA3 KD, we performed
a rescue experiment by re-expressing EphA3 with a mutated
shRNA binding site in U251 constitutive EphA3 KD cells (Figures
S2C and S2D). Following re-expression of shRNA-resistant
EphA3, both proliferation and tumorsphere-forming capacity
were restored.
We further compared EphA3 expression in the primary lines
following growth factor withdrawal and addition of 2% fetal
bovine serum (FBS), conditions that allow differentiation to occur
(Figure 2G). In each case EphA3 levels decreased in serum-
containing medium, providing further evidence that EphA3 is
downregulated during GBM cell differentiation. When recultured
in serum-free medium, EphA3 levels increased to preserum
culture levels with a parallel decrease in differentiated cells
(data not shown). To demonstrate that EphA3 was expressed
on less differentiated cells, we assessed the expression of
EphA3 compared to the expression of GFAP, a marker of astro-
cytes, in both patient specimens and GBM tumor xenografts.
Immunohistochemistry (IHC) results are shown for sequential
tissue sections from a GBM patient specimen and GBM xeno-
graft using BAH1 cells (Figures 2H and S2G). These show
a specific and discrete pattern of staining for EphA3 and
GFAP, implying that EphA3 expression is high on less differenti-
ated tumor cells and reduced on the differentiated population.
EphA3 Is Coexpressed with Markers of Undifferentiated
Cells in GBM
Of the markers of less differentiated, highly proliferative cells in
GBM that have been reported in the literature, among the most
convincing have been CD133, integrin a6, and CD15 (Lathia
et al., 2010; Singh et al., 2004; Son et al., 2009). To investigate
if EphA3 is coexpressed with these markers, we examined nine
acutely dissociated GBM specimens using multiparameter flow
cytometry, using the epidermal growth factor (EGF) receptor as
a positive control (Figure 3A). Specimens did not show distinct
subpopulations, but EphA3 appeared to be commonly coex-
pressed with integrin a6 but not CD133 (complete analysis and
controls shown in Figure S3A). Association with these markers
was further confirmed in the primary lines using both Amnis
expression analysis (Figure 3B) and flow cytometry (Figure 3C)Cshowing that EphA3 is most often coexpressed with integrin a6
and CD133 but not with CD15 (for complete flow cytometry anal-
ysis and controls see Figure S3B). Given that primary serum-free
cultures grown on laminin are reported to enrich for the dediffer-
entiated, highly proliferative cells known to express such
markers as CD133, integrin a6, and CD15, we assessed the
expression of EphA3 using three primary GBM tissue specimens
and the paired primary serum-free culture. Results show that
EphA3 expression was increased under these culture conditions
(Figure 3D). Despite two tissue specimens expressing low levels
of EphA3, all samples showed a significant increase in EphA3
expression following culture for 3 weeks. We also assessed
the expression by qPCR of neural and other progenitor cell
markers in WK1 cells transfected with control shRNA versus
EPHA3 shRNA (Figure 3E). Results show a reduced expression
of all these markers following EphA3 KD. Next, we sorted each
primary culture into high and low EphA3 fractions and assessed
the expression of progenitor cell markers, proliferation, and
sphere-forming potential (Figures 3E and S3C). In each case,
expression of at least one marker was elevated in the EphA3-
high population; in the case of the mesenchymal line WK1, all
markers were elevated in the EphA3-high fraction (Figure 3E).
Moreover, in all lines tested, the EphA3-positive population
showed a significantly (p < 0.05) higher capacity to form
tumorspheres and to proliferate at a higher rate. Furthermore,
IHC and immunofluorescence staining for CD31 and EphA3 in
the same GBM xenograft section revealed that EphA3 was
predominantly localized around the tumor vasculature (Figures
3F and S2G), a reported niche for GBM stem/progenitor cells
(Calabrese et al., 2007). Thus, we have presented several lines
of evidence that EphA3 is coexpressed with known markers of
undifferentiated cells in both clinical specimens and primary
cultures. This is in keeping with the finding that EphA3 is most
commonly elevated in mesenchymal GBM, which are character-
ized by the presence of progenitor cell markers and lack of neural
differentiation markers. Furthermore, EphA3 appears to be most
commonly coexpressed with integrin a6, a GBM progenitor cell
marker known to be expressed in the vascular bed of GBM
tumors (Lathia et al., 2010).
EphA3 Limits MAPK Pathway Activation
Previous studies have shown that EphA receptor activation can
lead to increased differentiation of neural precursor cells through
positive regulation of the extracellular signal-regulated kinase
(ERK) mitogen-activated protein kinase (MAPK) pathway (Aoki
et al., 2004). We examined ERK1/2 phosphorylation in both
WK1 and U251 cells and found that the ERK/MAPK pathway
was more highly activated in EphA3 KD cells compared to
control (Figures 4A and S4A). In contrast, the phosphatidylinosi-
tide 3-kinases/protein kinase B and Janus-activated kinase/
signal transducer and activator of transcription pathways
showed no change following EphA3 KD (data not shown). More-
over, when cells had been cultured without EGF, activation of the
MAPK pathway using either receptor tyrosine kinase (RTK)-
dependent (EGF) or RTK-independent (PMA [phorbol-12-myris-
tate-13-acetate]) stimulation resulted in prolonged and elevated
MAPK pathway activation when EphA3 was downregulated
(Figures 4B and S4B). This suggested that the differentiation
observed when EphA3 was neutralized could be due toancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc. 241
Figure 3. EphA3 Is Coexpressed with
Markers of Undifferentiated Cells in GBM
(A) EphA3 coexpression with the markers integrin
a6 and CD133 was assessed in GBM clinical
specimens (n = 9); EGFR was used as a positive
control. EphA3 was coexpressed with integrin a6,
while distinct subpopulations of EphA3- and
CD133-positive cells were observed in some of
the samples. See Figure S3 for complete analysis
and controls of nine specimens.
(B) Amnis expression analysis was performed on
three primary GBM cultures for EphA3 and the
markers integrina6, CD133, and CD15; represen-
tative individual and merged fluorescent images
are shown. Percentage of cells coexpressing
EphA3 and the marker of interest is quantitated for
each primary line (+SD, n = 3).
(C) EphA3 coexpression with the markers CD15,
CD133 and integrin a6 was assessed by flow
cytometry in three primary serum-free lines. Data
are shown for WK1. See Figure S3 for analysis of
BAH1 and SJH1.
(D) Flow cytometric analysis of paired GBM tumor
tissue and serum-free culture showing expression
of EphA3 is elevated under serum-free conditions
compared to the original patient specimen.
(E) Stem cell-like marker expression was assessed
in control shRNA versus EPHA3 shRNA seq 1WK1
cells. WK1 EphA3 KD cells showed a decrease in
all markers tested. Expression shown as the
percentage reduction in mRNA levels. Primary
serum-free cultures (BAH1, WK1, and SJH1)
were sorted into low and high EphA3 populations
and qPCR undertaken to determine expression
of undifferentiated markers, with expression
shown as copy number per 1,000 b-actin. See
Figure S3 for all primary lines tested. Sphere-
forming potential and proliferation were also found
to be significantly reduced in the EphA3-low
compared to EphA3-high cells for each of the
three primary lines (*p < 0.05, +SD; n = 3).
(F) Immunohistochemical and immunofluorescent
staining of BAH1 GBM xenografted tumor shows
coexpression of EphA3 and the endothelial cell
marker CD31. EphA3 (red) bright cells are primarily
found in close proximity to the tumor vasculature
(CD31+, green). Number of bright EphA3+ versus
dim EphA3+ cells was quantitated in a localization-dependent fashion; cells in close proximity to the CD31+ cells (within two layers of cells; white dashed lines
indicated boundaries) were compared to cells outside this region. Scale bar represents 20 mM. See also Figures S3A–S3D.
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EphA3 Is Functional and Targetable in GBMconstitutively elevated ERK/MAPK activation. Furthermore, re-
expression of EphA3 in U251 KD cells returned tumorsphere
formation in parallel with a loss of constitutively activated
ERK1/2 (Figure S4A). This suggested that EphA3 may be limiting
MAPK signaling and thereby restricting differentiation. To further
assess if ERKphosphorylation was indeed driving differentiation,
we overexpressed wild-type and constitutively active mitogen-
activated protein kinase kinases 1 and 2 (MEK1/2) in U251
wild-type tumorsphere cells and also downregulated ERK1/2
using small interfering RNA (siRNA) in EphA3 KD U251 tumor-
spheres (Figures S4C and S4D). MEK1/2 overexpression led to
constitutively active ERK1/2, resulted in a loss of tumorsphere
formation, and induced morphological changes indicative of
differentiation and reduced cell growth. This phenomenon was
reversed in EphA3 KD cells when ERK1/2 levels were reduced242 Cancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc.by siRNA-mediated KD, restoring tumorsphere formation.
Another Eph receptor, EphA2, has been shown to be frequently
overexpressed in GBM (Wykosky et al., 2005). We found that
EphA2 was coexpressed with EphA3 on many GBM patient
samples (Table S1). Immunofluorescence staining of EphA2
and EphA3 in primary lines showed significant overlapping
expression patterns (Figure S4F). Some degree of association
of these proteins was demonstrated by immunoprecipitation of
both EphA2 and EphA3 in U251 tumorspheres and primary
serum-free cultures. Given the coexpression of the two recep-
tors, we examined the effect of EPHA2 shRNA-mediated KD in
U251 tumorspheres. Results confirmed that, similar to EphA3
attenuation, EphA2 KD prevented tumorsphere formation,
reduced proliferation (33%, p < 0.05), and resulted in sustained
ERK activation following EGF stimulation (Figure S4G).
Figure 4. EphA3 Limits MAPK Pathway Activation and Exhibits Low
Basal Receptor Activation In Vitro and In Vivo
(A) EphA3 KD in WK1 tumorspheres induces constitutive ERK1/2 activation.
(B) EphA3 KD in WK1 tumorspheres induces elevated ERK1/2 activation
following treatment with EGF (30 ng/ml).
(C) Immunoprecipitation of EphA3 following treatment of BAH1, WK1, and
SJH1 with soluble clustered ephrin-A5-Fc (1 mg/ml) for 10 min revealed rapid
receptor activation. No activation was detected in the unstimulated primary
cultures.
(D) Immunofluorescent staining of EphA3 in BAH1, WK1, and SJH1 cells
showed rapid internalization of EphA3/ephrin-A5 receptor and ligand
complexes following activation with ephrin-A5-Fc (10 mg/ml) for 20 min at
37C. EphA3 remained on the cell surface if activation was delayed by main-
taining the cells at 4C. Following ephrin-A5-Fc treatment, pronounced cell
spreading and adhesion were observed.
(E) Flow cytometric analysis revealed a mild reduction of EphA3 on the cell
surface following treatmentwith ephrin-A5-Fc (10mg/ml) for 6 and24hr inBAH1
WK1 and SJH1 cells; expression is compared to control CD48-Fc (24 hr).
(F) Immunoprecipitation of EphA3 in two GBM tissue specimens reveals total
EphA3 was present while no receptor activation was detected.
(G) qPCR expression analysis of EPHA3 and EPHRIN A5 in BAH1, WK1, and
SJH1 shows elevated receptor expression compared to low ligand. Scale bar
represents 20 mM. See also Figures S4A–S4G.
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EphA3 Is Functional and Targetable in GBMAoki et al. (2004) showed that EphA3 activation could drive
neural cell differentiation through increased MAPK pathway
activation, whereas our data showed that EphA3 maintains
an undifferentiated, self-renewing tumor population through a
mechanism that limits MAPK signaling. We investigated the
activation status of EphA3 in GBM cells with or without stimula-
tion with the high-affinity ligand ephrin A5. The three primary
lines tested showed low levels of kinase activity in unstimulated
cultures, but the kinase was readily activated in response toCstimulation with clustered ephrin A5-Fc in all lines (Figure 4C).
Furthermore, EphA3 activation also led to an increase in cell
spreading and rapid internalization of receptor complexes (Fig-
ure 4D), and consequently a reduction in cell-surface EphA3
expression (Figure 4E). To determine if the low kinase activity
in vitro reflected the activation status in vivo, we tested its activa-
tion state in GBM patient specimens. Although EphA3 was ex-
pressed in patient samples, we could not detect kinase activity
(Figure 4F). qPCR expression analysis revealed that EPHRIN
A5 expression is low in all lines (Figure 4G), which is in keeping
with the expression analysis in a larger group of primary lines
tested (Figure S1). Receptor activation in U251 resulted in
a reduction in proliferation when high concentrations of ephrin
were used (Figure S4). Because the ephrin is cleaved during
internalization, we assume the high concentration is needed to
maintain continued internalization of Eph receptor. Ephrin A5-
Fc may also activate EphA2. Therefore, to exclude an EphA2-
mediated effect, we treated U251 cells with ephrin A5-Fc
following EphA2 downregulation using shRNA (Figure S4H).
The EphA2 KD cells showed an ephrin A5-Fc-stimulated reduc-
tion in proliferation similar to control cells. We also specifically
activated EphA3 using the EphA3 monoclonal antibody (mAb)
IIIA4, which, like ephrin, results in rapid internalization (Fig-
ure 4SH) (Vearing et al., 2005). An EphA3-specific reduction in
proliferation was observed in U251 cells when stimulated with
IIIA4, while an EphA3-negative primary GBM line (L1-NS) was
unaffected. These data suggest that although EphA3 is present
and functional in GBM, it is most likely functioning in a kinase-
independent fashion to decrease MAPK signaling.
EphA3 Neutralization Attenuates Tumor Formation
Because EphA3 KD induced differentiation and reduced prolifer-
ation, we asked if tumorigenesis was affected. The U251 EPHA3
shRNA sequence 1 versus control shRNA cells were injected
subcutaneously into nonobese diabetic severe combined immu-
nodeficiency (NOD/SCID) animals (Figure S5A). There was
a dramatic reduction in tumor formation in the EphA3 KD group
when compared with controls. Control tumors reached the 1 cm
diameter endpoint at an average of 68 days. In contrast, all
EphA3 KD animals survived beyond 100 days without tumor
formation. The experiment was terminated at day 140, and at
autopsy only one animal was found to have a small lesion.
qPCR and IHC of EphA3 showed high expression in control
tumors whereas low or negligible expression was detected in
the single KD tumor. This small tumor also showed high expres-
sion of GFAP and bIII-tubulin mRNA and GFAP and caspase-3
protein compared to the controls (Figures S5B and S5C).
Given the unique microenvironment in the brain, we also
examined the antitumor potential of both EphA3 neutralization
and depletion of EphA3 on the formation of intracranial xeno-
grafts. Initially, U251 EphA3 KD versus control shRNA cells
were injected into the right hemisphere of NOD/SCID animals.
As in the subcutaneous xenograft model, a failure of tumor
formation was observed in mice injected with the KD cells (Fig-
ure 5SD), whereas control animals formed large, well-vascular-
ized, invasive tumors at an average of 78 days after implantation.
All EphA3 KD animals were free of tumor at autopsy on day 145
postimplantation. To exclude off-target shRNA effects, mutant
EphA3 rescue cells were also analyzed. Control shRNA andancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc. 243
Figure 5. EphA3 Ablation Induces Differen-
tiation and Delays GBM Tumor Progression
In Vivo
(A) Flow cytometric and qPCR expression analysis
of EphA3 in WK1 serum-free cells following
depletion of EphA3-expressing cells using the
IIIA4 mAb bound to magnetic beads. Depleted
cells were compared to a mock-depleted control.
(B) Orthotopic xenograft experiments were con-
ducted using groups of six NOD/SCID mice in-
jectedwith 13 103, 13 104, and 13 105WK1 cells
depleted of EphA3 compared to a mock-depleted
control. Tumor formation was monitored using
in vivo luminescence imaging (Xenogen) over
100 days. Representative images are shown for
the 1 3 105 depleted versus control experiment
(complete imaging data are shown in Figure S5).
(C) Luminescence imaging of tumor formation was
quantitated and showed a significant (p < 0.05)
reduction in signal between groups. A reduction in
tumor formation was observed for all EphA3-
depleted groups compared to controls.
(D) Kaplan-Meier survival curves of the 13 103 and
13 105 cohorts for the WK1 EphA3-depleted cells
compared to the mock-depleted control. Deple-
tion of EphA3-expressing cells improved survival
compared to the control groups.
(E) qPCR expression analysis of EPHA3 and the
markers INTEGRIN a6,CD133, andCD15 inmock-
versus EphA3-depleted tumors (+SD, n = 2).
(F) Orthotopic xenograft experiment in NOD/SCID
animals using tumor cells from a GBM patient
specimen, which had been dissociated and
acutely sorted for high versus low EphA3 pop-
ulations. A total of 53103 tumor cellswere injected
per animal with six animals per group. The Kaplan-
Meier survival curve shows EphA3-positive cells
formed tumors with a median survival of 113 days, while no tumor formation was observed in EphA3-low cell-injected animals following 180 days (p = 0.003).
(G) A representative coronal H&E section of a tumor formed after injection of EphA3-positive patient tumor cells. Tumors were highly infiltrative and invasive
(complete H&E sections for each animal are shown in Figure S5). Scale bar represents 20 mM. See also Figures S5A–S5H.
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formation was monitored (Figure S5E). The control tumors
(n = 3) reached 1 cm in diameter in an average of 30 days, while
the rescue tumors (n = 4) reached 1 cm in diameter in an average
of 46 days. The somewhat slower growth of the rescue tumors
may reflect the slightly lower EphA3 expression in the rescue
cells but confirmed that EphA3 re-expression restored tumori-
genic potential.
To confirm that EphA3 is present on tumor cells and not the
stromal elements within the tumor, we orthotopically trans-
planted 5 3 104 tumor cells dissociated directly from a GBM
patient specimen into an immune-compromised NOD/SCID
animal. Five months following injection, a large invasive tumor
was detected. We subsequently analyzed the expression of
EphA3 in combination with the human-specific marker major
histocompatibility complex class I, human leukocyte antigens
(HLA) A, B, and C. Results show a clear separation between
nonhuman (mouse) stromal elements that were negative for
both EphA3 and HLA-A, B, and C within the tumor and EphA3-
positive HLA-A, B, and C tumor cells (Figure 5SF).
To explore whether the observation that EphA3 expression
was higher on less differentiated cells and therefore whether
low-EphA3 cells might translate into reduced tumorigenicity,244 Cancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc.we conducted an intracranial EphA3 depletion xenograft exper-
iment using the WK1 primary line infected with a luciferase-
encoding lentivirus. Because the EphA3 monoclonal antibody
may have activating properties, we initially avoided positive fluo-
rescence-activated cell sorting (FACS) selection and instead
compared mock-depleted versus the EphA3 mAb (IIIA4) anti-
body-depleted cells. As expected, depletion reduced EphA3
levels and also reduced the proliferative and sphere-forming
potential of the cells (Figures 5A and S5G). Cohorts of animals
were injected intracranially with 1 3 103, 1 3 104, and 1 3 105
cells and tumor formation monitored using in vivo luminescence
imaging (Figure 5B; for complete analysis see Figure S5G).
Tumor luminescence was quantitated and showed a significant
(p < 0.05) reduction in signal between mock and control for
each injection group (Figure 5C). The protumorigenic effect of
EphA3 expression was further confirmed by the survival curves,
which showed a significant difference in survival. The median
survival for the 1 3 103 group was mock 134 days versus
depleted 158 days and for the 1 3 105 group was mock
105 days versus depleted 120 days (Figure 5D). When animals
were culled, the tumor was resected and qPCR expression anal-
ysis performed for EPHA3 and markers of less differentiated,
highly proliferative cells (Figure 5E). Results showed a minimal
Figure 6. Lutetium-Radiolabelled Anti-
EphA3 (IIIA4) mAb Induces Apoptosis and
Prevents Tumor Formation
(A and B) U251 (A) and BAH1 (B) cell cultures were
treated with unlabeled DOTA-IIIA4 mAb or esca-
lating doses of 177Lu-IIIA4 mAb. At 48 and 96 hr,
apoptosis and cell death were analyzed by An-
nexin V and 7-AAD staining. Representative
density plots are shown for the 96 hr time point
(inset) after treatment with 4Gy of 177Lu-IIIA4mAb.
Early apoptotic cells were significantly (p < 0.01)
higher for all doses and time points compared to
cells treated with DOTA-IIIA4 mAb (0 Gy).
(C and D) U251 (C) or BAH1 (D) tumors were grown
subcutaneously in BALB/c nudemice (five animals
per group). Tumors (50 mm3) were treated with
DOTA-IIIA4 mAb (50 mg per mouse) or escalating
doses of 177Lu-IIIA4 mAb (50 mg per mouse). Data
are shown as percentage change in tumor volume
compared to day 0 (before treatments). Tumor
growth curves are shown for individual mice in
each treatment group. Insets show Kaplan-Meier
survival plots based on tumor volume. One animal
bearing a U251 tumor in the 150 MBq/kg showed
tumor regrowth andwas humanely killed. The survival of 450MBq/kg 177Lu-IIIA4mAb-treatedmice within the 120-day observation period was 80%and 100% for
U251 and BAH-1 xenograft-bearing mice, respectively, whereas the survival after DOTA-IIIA4 mAb (0 MBq/kg) was 0%.
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mock-depleted tumors, implying that depleted cells had re-
expressed EphA3 by the time the tumors had fully formed.
As a more stringent test of the involvement of EphA3 on the
tumor-initiating cell population, a GBM patient tumor was disso-
ciated and acutely sorted for high versus low EphA3 expression.
A total of 53 103 cells from positive and negative fractions were
injected orthotopically into NOD/SCID mice (n = 6). The median
survival for the positive population was 113 days while no tumors
had been detected in the negative fraction at 180 days (Fig-
ure 5F). Coronal hematoxylin and eosin (H&E) sections were
prepared when animals showed signs of tumor formation. In
each case, animals injected with high-EphA3-expressing cells
uniformly developed highly infiltrative tumors (Figure 5G; for
complete analysis, see Figure S5H). Two animals injected with
low-EphA3-expressing tumor cells were culled due to signs of
illness, but no tumor formation was detected (Figure S5H).
Radiolabelled Anti-EphA3 mAb Treatment Prevents
Tumor Formation
The higher expression of EphA3 on dedifferentiated tumor cells
suggested that an EphA3-targeted therapy might extinguish
the tumor by eliminating the less differentiated, tumorigenic
compartment. To test this idea, we used the EphA3 mAb (IIIA4)
radiolabelled with lutetium-177 (177Lu) in mice bearing either
U251 or early passage BAH1 cell xenografts. In vitro studies
had shown that 177Lu-IIIA4 mAb treatment induced dose- and
time-dependent apoptotic cell death in both U251 (Figure 6A)
and BAH1 cells (Figure 6B) and reduced clonogenic survival
(50% loss of clonogenic survival at 3.5 Gy over 48 hr, data not
shown). In mice, following a single injection, the doubling time
of U251 tumors was 9.9 ± 0.1 days in DOTA-IIIA4 mAb-treated
mice compared to 26.6 ± 0.2 days in mice treated with
150 MBq/kg 177Lu-IIIA4 mAb (Figure 6C). Similarly, in BAH1,
150 MBq/kg 177Lu-IIIA4 mAb lengthened the tumor-doublingCtime from 12.7 ± 0.1 days in control DOTA-IIIA4 mAb-treated
mice to 30.1 ± 1 days (Figure 6D). Higher doses of 177Lu-IIIA4
mAb induced complete regression of both U251 (Figure 6C)
and BAH1 (Figure 6D) tumors for up to 9 weeks following treat-
ment. Between 9 and 17 weeks after treatments, regrowth was
observed in one out five mice bearing U251 xenografts treated
with 450 MBq/kg 177Lu-IIIA4 mAb (Figure 6C) and no regrowth
was observed in mice bearing the patient-derived BAH1 xeno-
grafts (Figure 6D). Importantly, we observed no weight loss or
any clinical signs of toxicity at any of the doses. Kaplan-Meier
survival plots (Figures 6C and 6D) based on the defined tumor
volume endpoint showed a significant increase in survival upon
treatment with 177Lu-IIIA4mAb (p < 0.0001). Given the prolonged
follow up after treatment, these results suggest that all tumori-
genic cells were effectively targeted by the therapy and at higher
doses had extinguished the tumor.
DISCUSSION
The current investigation identifies the EphA3 receptor as being
highly expressed on a significant proportion of gliomas and, in
particular, on the mesenchymal subtype of GBM. Several lines
of evidence show that EphA3 is often more highly expressed
on the undifferentiated, tumor-initiating cells. In the first instance,
EphA3 was shown to be more highly expressed in serum-free
culture systems lacking differentiated cells and was downregu-
lated when cells were differentiated. In tissue sections, the
expression of EphA3 was high in areas with few differentiated
(GFAP-positive) cells and lower in areas of positive GFAP
expression. We observed an association of EphA3 with integrin
a6 in patient specimens, a known marker of stem-like cells,
but not so clearly with CD133, consistent with heterogeneity
within the undifferentiated fraction in GBM (Lathia et al., 2010).
Importantly, we show that EphA3 has a critical role inmaintain-
ing GBM cells in an undifferentiated state by limiting MAPKancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc. 245
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resulted in partial differentiation and decreased proliferation.
Interestingly, if EphA3 was activated sufficiently to induce inter-
nalization, then the loss of EphA3 from the cell surface also re-
sulted in reduced cell growth, implying that a relatively small
loss of Eph receptor expression results in a shift in the balance
between undifferentiated, highly proliferative cells and more
differentiated, slowly dividing nontumorigenic cells. Indeed, we
show that in lines that coexpress EphA2 or EphA3, loss of either
is sufficient to alter this balance toward differentiation. Critically,
the presence of EphA3 was shown to be needed for the function
of tumor-initiating cells because loss of EphA3 was shown to
markedly reduce tumorigenic potential.
Sustained MAPK signaling is able to drive differentiation of
neural progenitors (Aoki et al., 2004). Moreover, EphA receptors
have been shown to direct differentiation of neural stem cells via
the MAPK pathway during CNS development. EphA3 is strongly
coexpressed with nestin, a marker of undifferentiated neural
cells, in the ventricular zone during murine development and in
neurosphere cultures (Aoki et al., 2004). We show that in GBM,
loss of EphA3 resulted in elevated MAPK signaling in parallel
with partial loss of neurosphere formation, reduced proliferation,
and the acquisition of differentiation markers. We show that
regulation of ERK/MAPK signaling by EphA3 in GBM is kinase
independent and also independent of the upstream activators
of MAPK signaling.
The preferential expression of EphA3 in mesenchymal GBM is
noteworthy. Mesenchymal tumors behave more aggressively
and have a poorer prognosis (Carro et al., 2010; Phillips et al.,
2006; Thiery, 2002). Notably, recurrent GBM is associated with
a shift to a more mesenchymal state (Phillips et al., 2006).
Studies of EphA3 knockout mice show that during heart devel-
opment, EphA3 expression, induced by EMT, has a critical role
in formation of atrioventricular valves and septa (Stephen et al.,
2007). These findings suggest that EphA3 expression may
increase as part of the switch to amoremesenchymal (sarcoma-
tous) phenotype.
We noted that approximately 40% of GBM clinical specimens
expressed significantly increased levels of EphA3 compared to
normal brain. A further 20%of specimens expressed lower levels
of EphA3 that were still elevated above normal brain tissues.
Interestingly, most tumors, when cultured on laminin under
conditions preventing differentiation, expressed EphA3 irre-
spective of subtype. Multiplex flow cytometric analysis of patient
specimens revealed a positive association of EphA3 and integrin
a6 but not other markers such as CD133. Based on these
studies, EphA3 is not restricted to but it is more highly expressed
on the less differentiated tumorigenic cells and more widely ex-
pressed in less differentiated tumors such as the mesenchymal
subtype (Phillips et al., 2006). In some cases, EphA3 appeared
to be prominently expressed around the tumor vasculature of
GBM xenografts, a known stem cell niche in GBM (Calabrese
et al., 2007). A recent study has shown that the laminin receptor
integrin a6, a key protein in extracellular matrix modulation, is
also localized in the perivascular niche and can regulate tumor-
initiating cells (Lathia et al., 2010).
To explore the potential of EphA3 as a therapeutic target, we
radiolabelled the EphA3 mAb (IIIA4) using lutetium-177. A single
dose of the labeled antibody showed pronounced efficacy in246 Cancer Cell 23, 238–248, February 11, 2013 ª2013 Elsevier Inc.preclinical models with very low toxicity. The failure of
tumors to regrow for 16 weeks following 177Lu-IIIA4 mAb treat-
ment strongly suggests that the treatment has targeted the
tumor-initiating cell compartment. This supports the develop-
ment of EphA3-based targeted therapies for the treatment of
GBM.
Significantly, we demonstrate that EphA3 plays an active role
in maintaining tumor cells in a dedifferentiated, tumorigenic
state. Moreover, EphA3 is most highly expressed in the more
aggressive and undifferentiated mesenchymal GBM subtype.
What then might be the benefits of therapeutic targeting of this
cell-surface receptor? EphA3 is expressed at low levels in adult
tissues, making it relatively tumor specific. More importantly, our
results suggest that such therapy can eliminate the tumor-
initiating cells, thereby stopping the tumor at its source.
EXPERIMENTAL PROCEDURES
Patient Tumors
This study was approved by the human ethics committee of the Queensland
Institute of Medical Research (QIMR) and Royal Brisbane and Women’s
Hospital (RBWH). All patients signed an approved consent form prior to
surgery. Specimens were examined by a neuropathologist to verify tumor
type and grade (Table S1).
GBM Cell Culture
Primary cell lines were derived from GBM specimens and maintained either
as primary serum-free cultures grown on laminin (Pollard et al., 2009) or as
tumorsphere cultures using StemPro NSC SFM (Invitrogen). The ATCC GBM
cell line U251 was cultured in RPMI 1640 media containing 10% FBS or
cultured as tumorspheres. All cultures were grown at 37C under 5% CO2/
95% humidified air.
PCR Analysis
RNA was extracted using TRIzol (Invitrogen). First strand cDNA was synthe-
sized using random hexamers and Superscript III (Invitrogen). Real-time
PCR was carried out using SYBR Green (Applied Biosystems). Cycling condi-
tions and primers are listed in Supplemental Experimental Procedures.
shRNA Knock Down
EPHA3 shRNA seq 1 was cloned into pSuperior.neo+gfp (Oligoengine). The
inducible KD systemwas generated using the tetracycline repressor construct
pcDNA 6/TR (Invitrogen). EPHA3 shRNA seq 2 and control construct was the
mission lentivirus SCHLNV, Clone ID TRCN0000196830 (Sigma). shRNA
sequences are listed in Supplemental Experimental Procedures.
Multiplex Analysis
Two eight-color multiplex analysis was conducted on nine GBM specimens.
Cells were selected using a viability dye, hematopoietic lineage cells were
excluded using CD45, and CD56 was used to select cells of neural and glial
lineage. Cells were analyzed on a LSR 2 (BD); data analysis was carried out
using Treestar FlowJo software (version 7.6.4). Antibodies are listed in Supple-
mental Experimental Procedures.
Amnis Image Stream
Samples were run on an ImageStreamx as previously described (Haney et al.,
2011) with minor modification. Briefly, 5,000 events were collected for each
sample and single color controls used to create a compensation matrix to
correct for spectral overlap. All data were then analyzed using IDEA software
(Amnis Corporation, Seattle, WA, USA).
Amnis, IHC, Immunofluorescence, FACS, and Western Blotting
Antibodies
For IHC, GFAP (Biocare medical CM065B, 1:1,000), EphA3 in-house mAb
(IIIA4, 1:100), and CD31 (Santa Cruz sc1506, 1:100) were used.
Cancer Cell
EphA3 Is Functional and Targetable in GBMFor FACS/immunofluorescence, EphA2 in-house mAb (1F7, 5 mg/ml) and
EphA3 in-housemAb (IIIA4, 5 mg/ml), CD133 (Miltenyi AC133, 1:10), bIII-tubulin
(Promega G712A, 1:100), GFAP (DAKO 20334, 1:100), Integrin a6 (Millipore
CBL458, 1:100), myelin basic protein (Sigma M3821, 1:100), and control
IgG1 (BD 349040, 1:400) were used.
For western blotting, we used EphA3 in-house rabbit polyclonal (1:2,000),
Upstate antibodies ERK1/2 (06-182, 1:1,000), p-ERK1/2 (05-797, 1:1,000),
Akt1 (AB3137, 1:1,000), and p-Akt1 (1:1,000), and Stat3 (Santa Cruz 81523,
1:1,000). b-actin was used as a loading control (Sigma, 1:2,000).
Subcutaneous and Orthotopic Xenografts
This study was approved by the QIMR animal ethics committee. Experiments
were conducted using 5-week-old NOD/SCID mice. A total of 2 3 106 cells
were injected subcutaneously and animals were sacrificed when tumors ex-
ceeded 1 cm in diameter. A total of 1 3 105 (for U251 experiments), 1 3 103,
1 3 104, 1 3 105 (for WK1 depletion experiments), and 5 3 103 (for acutely
sorted clinical specimen) cells were injected intracranially using a stereotactic
device at a depth of 3 mm into the right cerebral hemisphere. Animals were
sacrificed when they showed signs of tumor formation (hunching, weight
loss, rough coat).
In Vitro and In Vivo Treatment Using 177Lu- IIIA4 mAb
For in vitro studies, 177Lu-IIIA4 mAb (preparation described in Supplemental
Experimental Procedures) was diluted to achieve a cumulative dose based
on the dose rate constant of 177Lu being 0.283 g.rad/mCi.hr (Kocher, 1981).
U251 and BAH1 GBM cultures were subjected to treatments with escalating
doses (0–4 Gy) of 177Lu-IIIA4 mAb for 48 or 72 hr and assayed for apoptosis
using Annexin V and 7-ADD.
For in vivo studies, BALB/c nude mice were injected subcutaneously with
2 3 106 U251 or BAH1 cells. Treatments with unlabeled DOTA-IIIA4 mAb or
escalating doses of 177Lu-labeled DOTA-IIIA4mAbwere initiated when tumors
reached 50 mm3. Unlabeled or labeled IIIA4 mAb was administered intrave-
nously as a single dose. Animals were monitored for clinical signs of toxicity
and tumor formation was monitored twice weekly by calliper measurement
(detailed in Supplemental Experimental Procedures).
Immunoprecipitation
Serum-starved cultures were lysed in cold lysis buffer and precleared using
CnBr inactivated beads. Total protein (2–5mg) was preincubated with either
EphA2 (1F7), EphA3 (IIIA4), or EGFR (528) antibodies (1 mg per 1 mg protein)
for a minimum of 2 hr at 4C. Prewashed protein G beads were added with
further incubation for 1 hr at 4C.
Statistical Analysis
A two-tailed Student’s t test determined the probability of difference and a
p value < 0.05 was considered significant. A c2 test was used to evaluate
significance of GBM subtypes. Correlation coefficient was determined using
parametric linear regression analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one table, five figures, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2013.01.007.
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